LATEST
Cencora agreed to acquire American Oncology NetworknewAPEX / KorainewSmith & Wesson Brands agreed to acquire Long Range IntermediatenewMaximus Federal Services agreed to acquire Agile DefenseMount Logan Management agreed to acquire Alternative Fund AdvisorsDime Commercial Bancshares / ES BancsharesSalesforce agreed to acquire BrazeJV Investors / Oro Mobility HoldingsMorgan Stanley Capital Partners acquired The Rapid GroupCBRE Group agreed to acquire Onnec GroupBevPoint Capital agreed to acquire ESGMarwynn Holdings acquired Zhituo Software
Open App
ClosedPublished 29 Dec 2022

argenx BV /
bluebird bio, Inc.

argenx BV buys priority review voucher from bluebird bio, Inc.

Price
$102.0m
Stage
Closed
Buy side: argenx BV
Buy sideargenx BV
Target: bluebird bio, Inc.
Targetbluebird bio, Inc.
Source · 29 Dec 2022
See the source
Buy side: argenx BV
Buy sideargenx BV
Target: bluebird bio, Inc.
Targetbluebird bio, Inc.
01 / Buyerargenx BV
02 / Targetbluebird bio, Inc.
01

What happened

argenx BV paid bluebird bio, Inc. $102.0 million in cash for a Rare Pediatric Disease Priority Review Voucher. The sale closed on Dec. 29, 2022.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

argenx BV buys priority review voucher from bluebird bio, Inc.

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    The source this page is built from.

  2. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.